The pharmaceutical industry is undergoing a transformation, driven by the integration of artificial intelligence (AI) in drug research and development (R&D). Sanofi, a major player, exemplifies this trend by optimizing drug target discovery through AI. Simultaneously, Amgen, in partnership with NVIDIA, explores generative AI to transform human data analysis and accelerate drug discovery. This dynamic is reinforced by strategic collaborations, such as the one between Pfizer and an Austrian institute, aimed at developing innovative AI models. However, these advancements come with regulatory and ethical challenges, necessitating a rapid adaptation of legislative frameworks.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
